Abstract
Following coverage from The ASCO Post, Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of Medical College of Wisconsin Cancer Center, comments on an adjuvant trial of a checkpoint inhibitor for clear cell renal cell carcinoma (RCC), real-world data comparing first-line platinum regimens for patients with metastatic urothelial carcinoma, and combination regimens for RCC.
